Herbal Mixture Extract for Atopic Dermatitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis, such as topical corticosteroids and tacrolimus, have side effects and limitations, necessitating the development of alternative therapeutic agents that are safe for long-term use without steroid-related issues.
Innovation Solution
A pharmaceutical, food, quasi-drug, and cosmetic composition incorporating a mixed extract of Phellodendri Cortex, Schizonepetae Spica, Sophorae Radix, Glycyrrhizae Radix, and Radix Rehmanniae Exsiccate at a 1:1:1:1 weight ratio, which suppresses immune responses and alleviates symptoms of atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids are used to treat atopic dermatitis, then anti-inflammatory effect is improved, but side effects such as atrophy and scleroderma occur
Solution Approach 1:
The patent replaces long-term steroid therapy with a natural herbal extract formulation that provides sustained anti-inflammatory protection without cumulative side effects. The composition uses Phellodendri Cortex, Schizonepetae Spica, Sophorae Radix, Glycyrrhizae Radix, Liriopis Tuber, and Radix Rehmanniae Exsiccate as renewable natural resources that do not deplete or cause atrophy like synthetic steroids.
Solution Approach 2:
The patent combines six different herbal extracts in a synergistic formulation where each component contributes specific anti-inflammatory, immunomodulatory, or skin-protective properties. This composite natural formulation replaces single-agent steroid therapy, providing multi-target action that achieves therapeutic efficacy while avoiding the narrow safety profile of corticosteroids.
2Object-affected harmful factors
If tacrolimus is used to treat atopic dermatitis, then safety is improved compared to corticosteroids, but long-term use causes counter effects and side effects
Solution Approach 1:
The patent shifts from synthetic immunosuppressant chemistry to natural phytochemical composition, changing the chemical parameter space to include flavonoids, tannins, saponins, and other plant-derived compounds. These natural compounds provide immunomodulation through multiple pathways that do not lead to tolerance or counter-effects associated with long-term tacrolimus use.
Solution Approach 2:
The natural herbal extracts in the formulation work through the body's own regulatory mechanisms rather than forcing immunosuppression. The composition supports the skin barrier function and modulates immune responses in a way that maintains physiological balance over time, avoiding the adaptive resistance that develops with prolonged tacrolimus therapy.
3Object-affected harmful factors
If natural product-based therapeutic agents are developed for atopic dermatitis, then safety and long-term use potential are improved, but therapeutic efficacy needs to be proven comparable to existing treatments
Solution Approach 1:
The patent merges six different herbal extracts into a single therapeutic formulation, combining their individual bioactivities into a synergistic whole. This combination approach allows the natural product to achieve therapeutic efficacy comparable to conventional treatments by targeting multiple inflammatory pathways simultaneously, while maintaining the safety advantages of natural compounds.
Data Source
Figure 1~2D
Figure 3A~3B
Figure 4A~4C
AI summary
Provided are a composition for treating atopic dermatitis including an herbal medicine mixed extract, and more particularly, a pharmaceutical composition, a food composition, a quasi-drug composition, and a cosmetic composition for preventing or treating atopic dermatitis, each composition including a mixed extract of Phellodendri Cortex, Schizonepetae Spica, Sophorae Radix, Glycyrrhizae Radix, Liriopis Tuber, and Radix Rehmanniae Exsiccate or a fraction thereof, and a method of treating atopic dermatitis using the pharmaceutical composition. The complex herbal medicine extract of the present invention may prevent, ameliorate, and treat atopic dermatitis to a degree similar or superior to those of the known therapeutic agents for atopic dermatitis.